Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
OBJECTIVE
To compare the effect of Parlodel SRO (Sandoz, Basel, Switzerland), a long-acting oral bromocriptine, to Parlodel (Sandoz) and to study the chronic effects of Parlodel SRO.


METHODS
The study was twofold: (1) random, double-blind and (2) open.


METHODS
Patients were studied in an academic environment.


METHODS
Hyperprolactinemic patients were selected. Sixteen patients were treated during 1 month. Ten patients completed the 1-year follow-up.


METHODS
Parlodel SRO or Parlodel was administered during 1 month (first 15 days: 5 mg/d; afterwards: 10 mg/d). Parlodel SRO was given during 1 year in variable doses (maximal 20 mg/d).


METHODS
Prolactin (PRL) levels, clinical improvement, and side effects were evaluated.


RESULTS
After 1 month, 63% of the patients in both groups had normal PRL and 43% had menses. Side effects were similar. After 1 year all patients except one had normal PRL levels, and 89% were ovulating.


CONCLUSIONS
The efficacy, tolerability, and long duration of action of Parlodel SRO make it an excellent alternative for the treatment of hyperprolactinemic patients.
Weingrill
C O
CO
Department of Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil.
Mussio
W
W
Moraes
C R
CR
Portes
E
E
Castro
R C
RC
Lengyel
A M
AM
D000284:Administration, Oral; D001971:Bromocriptine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008597:Menstrual Cycle; D008599:Menstruation Disturbances / Q000150:complications / Q000503:physiopathology; D010060:Ovulation; D011388:Prolactin / Q000097:blood; D011863:Radioimmunoassay
D001971:Bromocriptine; D011388:Prolactin